Lumida
/HTFL
⌘K
HTFL

HTFL

HTFL
$24.88USD↓-4.20%-1.09 today

MARKET CAP

2.1B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$25 – $26

52W RANGE

$20
$41

AI Summary

Stalk
TrimHigh

HTFL is entrenched in a Stage 4 decline with clear lower highs and lower lows. Price sits below all major EMAs, reinforced by a Support Failure pattern signaling buyers have ceded control. The medium-term bias is bearish, but extreme oversold conditions and a dampened RSI advise against aggressive selling. We defer further downside execution until any meaningful pullback is absorbed.

  • ↑Revenue $52.6M in Q1 2026, up 41% YoY; global case volume +67%.
  • ↑Wall Street unanimously rates HTFL a Buy; avg. price target $37.25.
  • ↓Negative earnings yield and weak profitability raise sustainability concerns.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

HeartFlow, Inc. (NASDAQ: HTFL) is a pioneering company specializing in cardiovascular diagnostics, harnessing advanced AI technology to improve patient care in the management of coronary artery disease (CAD). Positioned as a leader in the MedTech industry, HeartFlow's platform leverages a vast database of over 200 million annotated CCTA images to create personalized 3D models for accurate diagnoses. As healthcare transitions towards data-driven solutions, HeartFlow represents a key player in the evolving landscape of AI-enhanced medical technologies.

Bull says

  • ↑Revenue $52.6M in Q1 2026, up 41% YoY; global case volume +67%.
  • ↑Wall Street unanimously rates HTFL a Buy; avg. price target $37.25.
  • ↑Launched PCI Navigator tool to boost interventional cardiologist adoption.
  • ↑Ended Q1 with $254.9M cash, funding growth and R&D efforts.
  • ↑Strong clinical validation and physician education drive reimbursement uptake.
  • ↑High analyst revisions and robust liquidity indicators support upside.

Bear says

  • ↓Negative earnings yield and weak profitability raise sustainability concerns.
  • ↓High stock volatility indicates significant price swings and market uncertainty.
  • ↓Negative book-to-price ratio deters value-oriented investors.
  • ↓Short interest at 14% reflects skepticism on near-term performance.
  • ↓Adoption of new plaque analysis tool may lag until >70% coverage.
  • ↓Rising AI diagnostic competition threatens market share without innovation.

Investment themes with HTFL

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-20-2026bullish

Transcript signals

Bull points

  • In the first quarter of 2026, revenue was $52.6 million, up 41% year over year, on 67% global case growth.
  • The strength of our first quarter performance gives us confidence to raise our full year outlook. We now expect to deliver total revenue of $228 million to $232 million, representing 29% to 32% year-over-year growth.
  • we're raising our non-GAAP gross margin guidance to approximately 81%. This is the high end of our prior range, driven by ongoing AI efficiencies, volume leverage, and a higher mix of high margin plaque revenue.
Read full transcript analysis ›